Literature DB >> 23055861

Hypotension following cardiac surgery associated with paroxetine and mirtazapine withdrawal.

Kimberly J Novak1, William I Douglas, Robert J Kuhn.   

Abstract

This case describes a 15-year-old patient who experienced postoperative hypotension following an elective Ross procedure for aortic stenosis/insufficiency. The patient was taking paroxetine and mirtazapine for depression which were held prior to surgery. Hypotension occurred approximately eight hours postoperatively and required vasopressor support. Upon reinitiation of antidepressant therapy, hypotension resolved and vasopressor support was discontinued. A year later the patient required conduit replacement, and antidepressant therapy was weaned off during the three weeks prior to surgery. No hypotension was observed following the second surgery. Paroxetine withdrawal has been well-documented within adult literature, but there is little information regarding mirtazapine withdrawal. Furthermore, cardiovascular effects have not been well-documented, and even less is known within the pediatric population. Withdrawal symptoms in these agents may be explained by cholinergic rebound and/or rapid decline in serum concentrations upon abrupt discontinuation. It may be reasonable to consider tapering antidepressants with short half-lives prior to elective surgery in which patients may not be able to take maintenance medications for more than 24 hours.

Entities:  

Keywords:  antidepressants; hypotension; mirtazapine; paroxetine; thoracic surgical procedures

Year:  2008        PMID: 23055861      PMCID: PMC3462053          DOI: 10.5863/1551-6776-13.1.25

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  18 in total

1.  Withdrawal symptoms associated with paroxetine discontinuation in a nine-year-old boy.

Authors:  R S Diler; L Tamam; A Avci
Journal:  J Clin Psychopharmacol       Date:  2000-10       Impact factor: 3.153

2.  Withdrawal syndromes after paroxetine and sertraline discontinuation.

Authors:  G A Fava; S Grandi
Journal:  J Clin Psychopharmacol       Date:  1995-10       Impact factor: 3.153

3.  Mirtazapine withdrawal symptoms.

Authors:  F Benazzi
Journal:  Can J Psychiatry       Date:  1998-06       Impact factor: 4.356

4.  Serotonin reuptake inhibitor withdrawal.

Authors:  N J Coupland; C J Bell; J P Potokar
Journal:  J Clin Psychopharmacol       Date:  1996-10       Impact factor: 3.153

5.  Physical symptoms associated with paroxetine withdrawal.

Authors:  C Debattista; A F Schatzberg
Journal:  Am J Psychiatry       Date:  1995-08       Impact factor: 18.112

6.  Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine.

Authors:  N J Keuthen; P Cyr; J A Ricciardi; W E Minichiello; M L Buttolph; M A Jenike
Journal:  J Clin Psychopharmacol       Date:  1994-06       Impact factor: 3.153

7.  Paroxetine pharmacokinetics in depressed children and adolescents.

Authors:  R L Findling; M D Reed; C Myers; M A O'Riordan; S Fiala; L Branicky; B Waldorf; J L Blumer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1999-08       Impact factor: 8.829

Review 8.  Clinical pharmacokinetics of mirtazapine.

Authors:  C J Timmer; J M Sitsen; L P Delbressine
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

9.  A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.

Authors:  J S Price; P C Waller; S M Wood; A V MacKay
Journal:  Br J Clin Pharmacol       Date:  1996-12       Impact factor: 4.335

10.  Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.

Authors:  J F Rosenbaum; M Fava; S L Hoog; R C Ascroft; W B Krebs
Journal:  Biol Psychiatry       Date:  1998-07-15       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.